Logo

Lynx Signs Service Agreement with NIMH to Study Gene Expression in the Brain

May 21, 2004

NEW YORK, May 21 (GenomeWeb News) - Lynx Therapeutics has signed a service contract with the National Institute of Mental Health to study gene expression in the brain, the company said today.

 

Under the agreement, with the NIMH's Genes, Cognition, and Psychosis program, Lynx will use its Massively Parallel Signature Sequencing technology to analyze gene expression in a region of the brain cortex that has been implicated in schizophrenia.

 

Lynx will receive payments for its services on samples provided by NIMH.

Breaking News
The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.